Leap Therapeutics, Inc. (LPTX)
Fuera de horario:
Leap Therapeutics, Inc.
47 Thorndike Street
Suite B1-1
Cambridge, MA 02141
United States
617 714 0360
https://www.leaptx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 54
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Douglas E. Onsi J.D. | CFO, General Counsel, Treasurer & Secretary, President, CEO & Director | 1.04M | N/D | 1969 |
| Mr. Augustine J. Lawlor | Chief Operating Officer | 713.57k | N/D | 1957 |
| Dr. Cynthia A. Sirard | Chief Medical Officer | 708.64k | N/D | 1970 |
| Dr. Jason S. Baum Ph.D. | Chief Scientific Officer | N/D | N/D | 1979 |
| Mr. Mark O'Mahony | Chief Manufacturing Officer | N/D | N/D | 1971 |
| Ms. Christine M. Granfield | VP and Head of Regulatory Affairs & Quality | N/D | N/D | 1968 |
Descripción
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de Leap Therapeutics, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
